



Almac Group
2661 Audubon Road
Audubon, PA 19403 USA
Web: www.almacgroup.com
E-mail: info@almacgroup.com

North America
Tel: +1 (610) 666-9500
Fax: +1 (610) 666-9501

Europe
Tel: +44 2838 332200
Fax: +44 2838 332299

Who We Are

WITH OVER 30 YEARS EXPERIENCE serving over 600 clients including all the world leading pharmaceutical and biotech companies, Almac is a financially stable and privately owned organization employing 2,200 dedicated professionals within the US & EU.

Almac's aim is to provide the most comprehensive range of integrated drug development solutions to enable accelerated development from research through to commercialization.

Services Offered

ALMAC'S TRULY INTEGRATED APPROACH provides a seamless, fast and efficient route from drug discovery through to market.

Research

Almac provide genomics based solutions, informing drug discovery and enabling personalized medicine. Our services include:

- Biomarker Discovery & Validation
- Bioinformatic Solutions
- Genomic Services
- Medicinal Chemistry Support

Chemical & Pharmaceutical Development

Almac accelerate the development of customers' drug candidates through the effective integration of science and manufacturing to provide drug substance & product:

- API Supply
- Solid State Services
- Isotope Labeling
- Product Development
- Analytical Services
- Accelerated First In Man

Clinical Development

Almac is a recognized leader in the preparation of clinical trial supplies. Our technology solutions provide unrivaled access to data critical to the efficient management of clinical trials:

- Comparator Blinding
- Packaging & Labeling
- QP Release
- Global Distribution
- IVR / Web
- ePRO
- EDC

Commercial

Almac provides solid dosage form commercial manufacture and packaging for EU & US markets. Commercial support services facilitate EU market access for non-EU product:

- Commercial Manufacturing
- Commercial Packaging
- Commercial Support

New Developments

ALMAC IS INVESTING \$100m in a new North American headquarters facility based in Pennsylvania. Construction of the facility has commenced and it will be fully operational in 2010.

The number of distribution depots now managed by Almac Clinical Services has increased from 14 last year to 21 depots in 19 countries. We expect further depots to be added going forward, which will be a pivotal factor in our distribution strategy.

Almac Clinical Services are continuing the expansion of our European site with a new purpose-built facility for controlled drug and refrigerated storage. The facility will provide up to 800 additional pallet spaces for refrigerated material. This coupled with the recent 70,000 cu. ft. expansion of our US storage facility enables Almac to continue catering for the continued growth in IMP cold chain services.

The introduction of Solid State Services allows our customers to rapidly optimize the physical form of drug substance and bioavailability of drug product.

Almac is also adding a further 16,000 sq. ft. of analytical capacity at its European headquarters in Northern Ireland. The \$18m self financed investment is a 3-floor extension to its current commercial manufacture building.

www.almacgroup.com

